ZCMD - Zhongchao (ZCMD) shares surge on contract renewal of pulmonary hypertension program

Zhongchao (ZCMD) soars 73% premarket after renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals" (PAH Project) in 2021. The PAH Project aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors' ability to solve clinical problems.PAH is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs.

For further details see:

Zhongchao (ZCMD) shares surge on contract renewal of pulmonary hypertension program